Font Size




Menu Style

  2024   2023   2022   2021   2019  

Q1 2024

Neuraminidase Inhibitors

Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract…read more

Recombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does not require permissive mutations to retain the replicative fitness in vitro and in ovo…read more


Baloxavir and Endonuclease Inhibitors

Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants…read more

Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus…read more

The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir…read more

Optimization and biological evaluation of l-DOPA derivatives as potent influenza PAN endonuclease inhibitors with multi-site binding characteristics…read more

Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands…read more


New Drug Discovery & Virucides

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus…read more

Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results…read more

Influenza A virus resistance to 4'-fluorouridine coincides with viral attenuation in vitro and in vivo…read more

Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus…read more


Clinical Trials & Case Studies

Outpacing antiviral resistance: new treatments for influenza virus infection…read more

Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey…read more

Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients…read more

Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial…read more

Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season…read more

Efficacy of Pharmacotherapy for Seasonal Influenza in Young and Middle-aged Adults: A Systematic Review and Network Meta-analysis…read more


Reviews & Commentary

Commentary: Randomized, placebo-controlled trial of antiviral treatment in patients hospitalized for influenza…read more



Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA